From Hit to Candidate: How Human-Relevant Models, Functional Genomics, and Early ADMET Are Transforming Drug Discovery
Drug discovery research is rapidly evolving with a clear shift toward human-relevant models, integrated biology, and smarter lead selection. Teams that combine advanced cellular systems, robust target validation, and careful translational planning are seeing faster progress from hit identification to candidate nomination.Human-relevant models: Organoids, primary cells, and microphysiological systems
Traditional cell lines and animal models often fail to predict human responses.
Incorporating organoids, induced pluripotent stem cell-derived tissues, and organ-on-chip platforms increases physiological relevance for efficacy and safety testing. These systems capture complex cell–cell interactions, metabolic activity, and tissue architecture, improving the likelihood that a candidate will perform in clinical settings. Use these models for secondary screening, mechanism-of-action studies, and biomarker discovery.
Functional genomics for target discovery and validation
CRISPR-based screens and other functional genomic tools enable unbiased identification of genes that drive disease phenotypes. Coupling loss- and gain-of-function screens with orthogonal validation—small-molecule probes, rescue experiments, and patient-derived material—strengthens target confidence. Prioritize targets with human genetic support and clear disease biology to reduce late-stage attrition.
Structure- and fragment-based approaches for lead discovery
Structure-based drug design remains a cornerstone for optimizing potency and selectivity. Fragment-based hit generation followed by iterative structure-guided elaboration can yield efficient, ligand-efficient leads. High-resolution structures of targets, including co-complexes with ligands, accelerate rational optimization of physicochemical properties and off-target profiles.
Phenotypic screening and target deconvolution
Phenotypic assays capture complex biology and can uncover novel mechanisms inaccessible to target-centric campaigns.
When a promising phenotype emerges, invest early in target deconvolution through transcriptomics, proteomics, chemoproteomics, and genetic perturbation. Combining phenotypic readouts with orthogonal mechanistic data yields more tractable pharmacology and clearer paths to clinical biomarkers.
Early ADMET and safety strategy
Predictive absorption, distribution, metabolism, excretion, and toxicity assessments should be integrated from the earliest lead optimization steps. Use human-relevant in vitro assays for hepatic metabolism, cardiac ion-channel liability, and mitochondrial toxicity.
Addressing safety liabilities early preserves medicinal chemistry bandwidth and reduces the risk of late-stage failures.
Drug repurposing and translational shortcuts
Repurposing approved or clinically-tested compounds can shorten timelines by leveraging existing safety data. Systematic screening of annotated libraries against new targets or phenotypes, supported by real-world evidence and human biomarker correlations, offers pragmatic translational opportunities. Prioritize repurposing candidates with suitable pharmacokinetics and a plausible exposure–response relationship for the new indication.
Data integration, reproducibility, and multidisciplinary teams
Robust data management, standardized assay protocols, and open sharing of negative results improve reproducibility and collective progress. Cross-disciplinary teams—biologists, chemists, clinicians, statisticians, and regulatory experts—are essential for designing clinically meaningful studies and biomarker strategies.
Early engagement with regulatory pathways clarifies preclinical requirements and expedites clinical translation.
Practical takeaways
– Favor human-relevant models for translational confidence.
– Combine functional genomics with orthogonal validation for target selection.
– Use structure- and fragment-based design to optimize leads efficiently.
– Incorporate ADMET profiling early to de-risk candidates.
– Explore repurposing as a pragmatic route to clinic.
– Invest in data standards, reproducibility, and multidisciplinary collaboration.
Adopting an integrated, biology-first approach—backed by rigorous chemistry and translational planning—improves the odds of delivering safe, effective therapies to patients.